ZA959416B - Carrier protein having an adjuvant effect immunogenic complex containing it process for their preparation nuclofotide sequence and vaccine - Google Patents

Carrier protein having an adjuvant effect immunogenic complex containing it process for their preparation nuclofotide sequence and vaccine

Info

Publication number
ZA959416B
ZA959416B ZA959416A ZA959416A ZA959416B ZA 959416 B ZA959416 B ZA 959416B ZA 959416 A ZA959416 A ZA 959416A ZA 959416 A ZA959416 A ZA 959416A ZA 959416 B ZA959416 B ZA 959416B
Authority
ZA
South Africa
Prior art keywords
nuclofotide
vaccine
sequence
preparation
carrier protein
Prior art date
Application number
ZA959416A
Other languages
English (en)
Inventor
Hans Binz
Thierry Baussant
Jean-Francois Haeuw
Thien Nguyen
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of ZA959416B publication Critical patent/ZA959416B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/26—Klebsiella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/807—Hapten conjugated with peptide or protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
ZA959416A 1994-11-07 1995-11-07 Carrier protein having an adjuvant effect immunogenic complex containing it process for their preparation nuclofotide sequence and vaccine ZA959416B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9413306A FR2726472B1 (fr) 1994-11-07 1994-11-07 Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin

Publications (1)

Publication Number Publication Date
ZA959416B true ZA959416B (en) 1996-06-06

Family

ID=9468564

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA959416A ZA959416B (en) 1994-11-07 1995-11-07 Carrier protein having an adjuvant effect immunogenic complex containing it process for their preparation nuclofotide sequence and vaccine

Country Status (14)

Country Link
US (3) US6197929B1 (pt)
EP (1) EP0791063B1 (pt)
JP (1) JPH10508595A (pt)
AT (1) ATE287954T1 (pt)
AU (1) AU714423B2 (pt)
CA (1) CA2204510A1 (pt)
DE (1) DE69533961T2 (pt)
DK (1) DK0791063T3 (pt)
ES (1) ES2236718T3 (pt)
FR (1) FR2726472B1 (pt)
NZ (1) NZ296561A (pt)
PT (1) PT791063E (pt)
WO (1) WO1996014415A1 (pt)
ZA (1) ZA959416B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2726472B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin
FR2748476B1 (fr) * 1996-05-07 1998-08-14 Pf Medicament Complexe immunogene, son utilisation, son procede de preparation et vaccin le contenant
FR2766192B1 (fr) * 1997-07-17 2001-07-13 Pf Medicament Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
FR2776521B1 (fr) * 1998-03-27 2000-12-15 Pf Medicament Utilisation de conjugues p40 actifs par voie nasale
FR2785542B1 (fr) * 1998-11-06 2001-02-09 Pf Medicament UTILISATION D'UNE PROTEINE OmpA D'ENTEROBACTERIE, POUR LE CIBLAGE SPECIFIQUE D'UNE SUBSTANCE BIOLOGIQUEMENT ACTIVE QUI LUI EST ASSOCIEE VERS LES CELLULES PRESENTATRICES D'ANTIGENES TELLES QUE LES CELLULES DENDRITIQUES HUMAINES
FR2789588B1 (fr) * 1999-02-17 2001-05-04 Pf Medicament Utilisation d'une proteine ompa d'enterobacterie associee a un antigene dans une composition pharmaceutique destinee a generer ou accroitre une reponse cytotoxique antivirale, antiparasitaire ou antitumorale
FR2789902A1 (fr) * 1999-02-24 2000-08-25 Pf Medicament PROTEINE OmpA DE KLEBSIELLA PNEUMONIAE ASSOCIEE A LA CHAINE BETA DE L'HORMONE hCG OU A UN COMPOSE IMPLIQUE DANS LA PROLIFERATION DE CELLULES TUMORALES OU DANS LA FERTILITE, UTILE DANS UNE COMPOSITION PHARMACEUTIQUE
FR2790960B1 (fr) * 1999-03-15 2002-10-31 Pf Medicament Utilisation de fractions membranaires bacteriennes a activite immunostimulante dans le traitement de cancers, leurs procedes de preparation et les compositions pharmaceutiques les contenant
FR2790959B1 (fr) * 1999-03-15 2003-06-27 Pf Medicament Utilisation de fractions membranaires bacteriennes a effet adjuvant, leurs procedes de preparation et composition pharmaceutique les contenant
FR2798857B1 (fr) * 1999-09-23 2003-06-06 Pf Medicament Utilisation d'une proteine de membrane ompa d'enterobacterie associee a un peptide immunogene du vrs pour la preparation de vaccins administrables par voie nasale
FR2803302B1 (fr) * 2000-01-04 2004-12-10 Pf Medicament Procede de preparation d'un polypeptide soluble en solvant aqueux en absence de detergent
FR2808445A1 (fr) * 2000-05-04 2001-11-09 Pf Medicament Proteine omp associee a un lysat de cellules tumorales autologues et/ou heterologues
FR2809014A1 (fr) * 2000-05-16 2001-11-23 Pf Medicament Utilisation d'une proteine ompa d'enterobacterie comme agent antimicrobien
FR2816844A1 (fr) * 2000-11-17 2002-05-24 Pf Medicament Domaine periplasmique d'une proteine omp d'enterobacterie et son utilisation comme porteur et/ou adjuvant
FR2828106A1 (fr) * 2001-08-02 2003-02-07 Pf Medicament Utilisation d'une omp d'enterobacterie de faible masse moleculaire comme porteur et/ou adjuvant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989005823A1 (en) * 1987-12-23 1989-06-29 The Upjohn Company Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus
AU644470B2 (en) * 1990-08-31 1993-12-09 Pharmacia & Upjohn Company Hrsv vaccine
GB9200117D0 (en) * 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
FR2718452B1 (fr) * 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
FR2726472B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin

Also Published As

Publication number Publication date
EP0791063A1 (fr) 1997-08-27
US6197929B1 (en) 2001-03-06
ATE287954T1 (de) 2005-02-15
FR2726472B1 (fr) 1997-01-31
NZ296561A (en) 2000-01-28
US20060034870A1 (en) 2006-02-16
DE69533961T2 (de) 2006-01-05
CA2204510A1 (fr) 1996-05-17
DE69533961D1 (de) 2005-03-03
FR2726472A1 (fr) 1996-05-10
WO1996014415A1 (fr) 1996-05-17
AU714423B2 (en) 2000-01-06
DK0791063T3 (da) 2005-06-06
JPH10508595A (ja) 1998-08-25
EP0791063B1 (fr) 2005-01-26
US7408044B2 (en) 2008-08-05
ES2236718T3 (es) 2005-07-16
AU4119996A (en) 1996-05-31
PT791063E (pt) 2005-06-30
US6780420B1 (en) 2004-08-24

Similar Documents

Publication Publication Date Title
ZA959416B (en) Carrier protein having an adjuvant effect immunogenic complex containing it process for their preparation nuclofotide sequence and vaccine
CA2281952A1 (en) Compounds for immunotherapy of prostate cancer and methods for their use
CA2158455A1 (en) Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide and their uses in vaccines and disease treatments
GR3031237T3 (en) Osp a proteins of borrelia burgdorferi subgroups, encoding genes and vaccines.
GEP20022695B (en) Moraxella Catarrhalis Outer Membrane Protein-106 Polypeptide, Gene Sequence and Uses Thereof
WO1998004702A3 (en) Proteins, in particular membrane proteins, of helicobacter pylori, their preparation and use
CA2067744A1 (en) The human c3b/c4b receptor (cr1)
RU95117238A (ru) Нуклеиновая кислота, рекомбинантная плазмида, рекомбинантный вектор, белок, синтетический пептид, химерная молекула, иммуногенная композиция, антисыворотка или антитела
HUP0103502A2 (hu) Streptococcus Cbéta-fehérje készítmények
WO1996003506A3 (en) Analog of haemophilus hin47 with reduced protease activity
AU684317B2 (en) Coccidiosis poultry vaccine
FI902569A0 (fi) Producering av till gonorre anslutande pi-proteiner och vaccin.
ZA965586B (en) Coccidiosis poultry vaccine
IL116026A (en) Peptides capable of linking to the sh3 domain of gap, nucleotide sequences encoding the same, their preparation and uses
AU3172095A (en) Coccidiosis poultry vaccine
GB9215232D0 (en) Vaccines
MY101874A (en) Vaccine
CA2006587A1 (en) Membrane proteins and peptides of haemophilus influenzae type b
CA2223503A1 (en) Transferrin receptor genes
NZ511360A (en) Protective recombinant haemophilus influenzae high molecular weight proteins
NZ512448A (en) Chlamydia antigens and corresponding DNA fragments and uses thereof